---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-003664"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:40:33.215295+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Entera Bio reports Q3 net loss $2.4M; advances oral peptide pipeline with OPKO collaboration, Phase 3-ready EB613

## Summary
- Net loss $2.4M ($0.08/share) vs $3.1M ($0.11) in Q3 2022; cash $7.6M sufficient into Q3 2024.
- FDA concurred that 2-year Phase 3 study with BMD endpoint could support NDA for EB613 (oral PTH) in osteoporosis.
- Collaboration with OPKO to develop oral GLP-2 for short bowel syndrome and oxyntomodulin for obesity; updates expected H1 2024.
- EB612 (oral PTH for hypoparathyroidism) Phase 2a met endpoints; ongoing PK/PD study results expected end of 2023.
- Operating expenses $2.4M, down from $2.9M YoY.

## SEC filing metadata
- accession: 0001178913-23-003664
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891323003664/0001178913-23-003664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891323003664/zk2330537.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-003664
- JSON: https://secwatch.observer/filing/0001178913-23-003664.json
- Plain text: https://secwatch.observer/filing/0001178913-23-003664.txt

## Key facts
- Earnings Releases
  Entera Bio Ltd. reported financial results for the third quarter ended September 30th, 2023.
  - Period: the third quarter ended September 30th, 2023
  - Result: reported results
  source text: On November 14, 2023, Entera Bio Ltd., a company organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891323003664/0001178913-23-003664-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.